All In Biotech

Drug Trial Radar · NCT02557789

Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects

A Study to Assess the Bioavailability and Pharmacokinetics of an Immediate Release Tablet Formulation of Lefamulin When Administered to Fed and Fasted Healthy Subjects in Comparison to an Intravenous Formulation and a Capsule Formulation

Last checked: Nov 19, 2026Latest source record: Sep 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jun 2015

Primary completion

Jun 2015

Study completion Jun 2015

Sponsor

Lead sponsor
Nabriva Therapeutics AGIndustry
Sponsor type
Industry
First posted
Sep 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1 study to assess the bioavailability and pharmacokinetics of a 600 mg immediate release tablet formulation of lefamulin when administered to fed and fasted healthy subjects in comparison to an intravenous formulation and a capsule formulation.

Conditions

  • Healthy

Interventions

  • LefamulinDrug

    Lefamulin administered iv or orally in the fasted state and orally in the fed state

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The area under the concentration time curve (AUC) of an intravenous and oral formulation of lefamulin in the fasting stateTime frame: 36 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Clinical

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.